• Je něco špatně v tomto záznamu ?

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis

HP. Hartung, BAC. Cree, M. Barnett, SG. Meuth, A. Bar-Or, L. Steinman

. 2023 ; 14 (-) : 1290666. [pub] 20231129

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007893

Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in the central nervous system play a critical role. To our knowledge, alemtuzumab, fumarates (dimethyl, diroximel, and monomethyl), glatiramer acetates, interferons, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, and teriflunomide are either limited to the periphery or insufficiently studied to confirm direct central nervous system effects in participants with multiple sclerosis. In contrast, cladribine and sphingosine 1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are central nervous system-penetrant and could have beneficial direct central nervous system properties.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007893
003      
CZ-PrNML
005      
20240423160350.0
007      
ta
008      
240412e20231129sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2023.1290666 $2 doi
035    __
$a (PubMed)38162670
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany $u Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia $u Department of Neurology, Medical University of Vienna, Vienna, Austria $u Department of Neurology, Palacký University Olomouc, Olomouc, Czechia
245    10
$a Bioavailable central nervous system disease-modifying therapies for multiple sclerosis / $c HP. Hartung, BAC. Cree, M. Barnett, SG. Meuth, A. Bar-Or, L. Steinman
520    9_
$a Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in the central nervous system play a critical role. To our knowledge, alemtuzumab, fumarates (dimethyl, diroximel, and monomethyl), glatiramer acetates, interferons, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, and teriflunomide are either limited to the periphery or insufficiently studied to confirm direct central nervous system effects in participants with multiple sclerosis. In contrast, cladribine and sphingosine 1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are central nervous system-penetrant and could have beneficial direct central nervous system properties.
650    _2
$a lidé $7 D006801
650    12
$a roztroušená skleróza $x farmakoterapie $7 D009103
650    _2
$a imunosupresiva $7 D007166
650    12
$a relabující-remitující roztroušená skleróza $7 D020529
650    _2
$a kladribin $7 D017338
650    12
$a nemoci centrálního nervového systému $7 D002493
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cree, Bruce A C $u Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, United States
700    1_
$a Barnett, Michael $u Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia
700    1_
$a Meuth, Sven G $u Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
700    1_
$a Bar-Or, Amit $u Center for Neuroinflammation and Experimental Therapeutics, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
700    1_
$a Steinman, Lawrence $u Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, United States
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 14 (20231129), s. 1290666
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38162670 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160346 $b ABA008
999    __
$a ok $b bmc $g 2081728 $s 1217660
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1290666 $e 20231129 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

    Možnosti archivace